Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 132-145
Open Access | Times Cited: 52

Showing 26-50 of 52 citing articles:

Protein Haptenation and Its Role in Allergy
Maja Aleksić, Xiaoli Meng
Chemical Research in Toxicology (2024) Vol. 37, Iss. 6, pp. 850-872
Open Access | Times Cited: 3
Unlocking the potential of bispecific ADCs for targeted cancer therapy
Hongye Zeng, Wenjing Ning, Xue Liu, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 4, pp. 597-621
Closed Access | Times Cited: 3
Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical
Yichao Kong, Caihong Jiang, Guifeng Wei, et al.
Molecules (2023) Vol. 28, Iss. 12, pp. 4672-4672
Open Access | Times Cited: 8
Multi-omic stratification of the missense variant cysteinome
Heta S. Desai, Samuel Ofori, Lisa M. Boatner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
Integrative analysis of single-cell and bulk RNA-sequencing data revealed T cell marker genes based molecular sub-types and a prognostic signature in lung adenocarcinoma
Yue-Ling Peng, Yafang Dong, Qihui Sun, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
Alexandria P. Eiken, Audrey L. Smith, Sydney A. Skupa, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 5, pp. 1328-1343
Open Access | Times Cited: 2
KRAS mutations in endometrial cancers: Possible prognostic and treatment implications
Karolina A. Kilowski, Martin Dietrich, Joanne Xiu, et al.
Gynecologic Oncology (2024) Vol. 191, pp. 299-306
Open Access | Times Cited: 2
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers
Adrienne D. Cox, Jenny P.‐Y. Ting, Channing J. Der
Cancer Discovery (2023) Vol. 13, Iss. 1, pp. 19-22
Closed Access | Times Cited: 6
A platform for mapping reactive cysteines within the immunopeptidome
Chenlu Zhang, Chen Zhou, Assa Magassa, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Molecular basis for antibody recognition of multiple drug–peptide/MHC complexes
Lorenzo Maso, Epsa Rajak, Injin Bang, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 22
Open Access | Times Cited: 1
The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
Alexandria P. Eiken, Elizabeth Schmitz, Erin M. Drengler, et al.
Hemato (2024) Vol. 5, Iss. 3, pp. 321-340
Open Access | Times Cited: 1
Chemoproteogenomic stratification of the missense variant cysteinome
Heta S. Desai, Katrina H. Andrews, Kristina V. Bergersen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Generation of tumor neoantigens by RNA splicing perturbation
Adi Rosenberg-Mogilevsky, Zahava Siegfried, Rotem Karni
Trends in cancer (2024)
Closed Access | Times Cited: 1
Strategies to boost antibody selectivity in oncology
Vincent Blay, Atanasio Pandiella
Trends in Pharmacological Sciences (2024)
Open Access | Times Cited: 1
Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical
Yichao Kong, Caihong Jiang, Guifeng Wei, et al.
(2023)
Open Access | Times Cited: 3
Introduction
Shiva Malek, Frank McCormick
Elsevier eBooks (2024), pp. xxxvii-xlii
Closed Access
Immune-oncology potential of KRAS inhibitors
Míriam Molina‐Arcas, Jesse Boumelha, Julian Downward
Elsevier eBooks (2024), pp. 443-462
Closed Access
Introduction to RAS biology
Channing J. Der, Frank McCormick
Elsevier eBooks (2024), pp. 1-36
Closed Access
Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain
Injin Bang, Takamitsu Hattori, Nadia Leloup, et al.
Nature Chemical Biology (2024)
Closed Access
A platform for mapping reactive cysteines within the immunopeptidome
Chenlu Zhang, Zhou Chen, Assa Magassa, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3
Elizabeth Schmitz, Abigail Ridout, Audrey L. Smith, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2857-2857
Open Access
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors
Mai Abdel Mouti, Siim Pauklin
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 255-257
Open Access | Times Cited: 1
Defining the Cell Surface Cysteinome using Two-step Enrichment Proteomics
Tianyang Yan, Lisa M. Boatner, Liujuan Cui, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy
Xinxin Song, Zhuan Zhou, Rui Kang, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Correction: Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy

Cancer Discovery (2023) Vol. 13, Iss. 4, pp. 1026-1026
Open Access

Scroll to top